What is the net share change from Vuong Trieu’s latest Oncotelic (OTLC) trades?

The transaction summary shows a net buy of 255,000 Oncotelic common shares. All three reportable transactions were purchases, with no reported sales, gifts, tax withholdings, or derivative exercises in this Form 4 submission.

Oncotelic CEO buys 255,000 shares in open market

Oncotelic Therapeutics, Inc. director, chairman, CEO and ten percent owner Vuong Trieu reported open-market purchases of a total of 255,000 shares of common stock at $0.045 per share over three days in late June 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. director, chairman, CEO and ten percent owner Vuong Trieu reported open-market purchases of a total of 255,000 shares of common stock at $0.045 per share over three days in late June 2026. He bought 65,000 shares on June 22, 75,000 shares on June 23, and 115,000 shares on June 24 in his individual capacity. Following these purchases, his directly held stake rose to 93,884,319 shares. The filing also lists additional indirect holdings of common stock, including 6,872,529 shares held by his spouse and 16,780,384 shares held by Autotelic Inc. as of June 22.

Insider Trade Summary

Net Buyer: 255,000 shares

Net Buy 5 txns

Insider Trieu Vuong

Role CHAIRMAN AND CEO

Bought 255,000 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	115,000	$0.045	$5K
Purchase	Common Stock	75,000	$0.045	$3K
Purchase	Common Stock	65,000	$0.045	$3K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 93,884,319 shares (Direct); Common Stock — 16,780,384 shares (Indirect, By Autotelic Inc.); Common Stock — 6,872,529 shares (Indirect, By spouse)

Footnotes (1)

F1. On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045.

Key Figures

Total shares purchased: 255,000 shares Purchase price: $0.045 per share Shares bought June 22, 2026: 65,000 shares +5 more

8 metrics

Total shares purchased 255,000 shares Open-market common stock buys in June 2026

Purchase price $0.045 per share All three open-market purchases

Shares bought June 22, 2026 65,000 shares Open-market purchase on June 22, 2026

Shares bought June 23, 2026 75,000 shares Open-market purchase on June 23, 2026

Shares bought June 24, 2026 115,000 shares Open-market purchase on June 24, 2026

Direct holdings after trades 93,884,319 shares Common stock directly owned after June 24, 2026

Indirect spouse holdings 6,872,529 shares Common stock held indirectly by spouse as of June 22, 2026

Indirect Autotelic Inc. holdings 16,780,384 shares Common stock held indirectly by Autotelic Inc. as of June 22, 2026

Key Terms

open-market purchase, ten percent owner, indirect ownership, By spouse, +1 more

5 terms

open-market purchase financial

"purchased 65,000 shares ... from the open market at a price of $0.045"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

ten percent owner financial

"Vuong Trieu is listed as a director, officer and ten percent owner"

indirect ownership financial

"entries show indirect ownership, including shares held by spouse and Autotelic Inc."

By spouse financial

"total_shares_following_transaction 6,872,529 with nature_of_ownership "By spouse""

By Autotelic Inc. financial

"total_shares_following_transaction 16,780,384 with nature_of_ownership "By Autotelic Inc.""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Oncotelic (OTLC) report for Vuong Trieu?

Oncotelic reported that chairman and CEO Vuong Trieu bought 255,000 common shares in three open-market trades at $0.045 per share. These purchases occurred on June 22, 23, and 24, 2026, and were made in his individual capacity.

How many Oncotelic (OTLC) shares does Vuong Trieu hold after these trades?

After the reported open-market purchases, Vuong Trieu directly holds 93,884,319 Oncotelic common shares. The filing also shows indirect holdings of 6,872,529 shares by his spouse and 16,780,384 shares held by Autotelic Inc. as of June 22, 2026.

At what price did the Oncotelic (OTLC) CEO buy new shares?

All three reported purchases by Oncotelic’s CEO were executed at $0.045 per common share. He bought 65,000 shares on June 22, 75,000 on June 23, and 115,000 on June 24, 2026, according to the Form 4 footnote.

Were the recent Oncotelic (OTLC) insider transactions open-market buys?

Yes. The Form 4 classifies each transaction with code P, described as an open-market or private purchase. Footnotes specify that on June 22, 23, and 24, 2026, Vuong Trieu bought shares from the open market at $0.045 per share.

Does the Oncotelic (OTLC) filing show indirect ownership for Vuong Trieu?

The filing shows indirect ownership entries dated June 22, 2026, including 6,872,529 Oncotelic common shares held by his spouse and 16,780,384 shares held by Autotelic Inc. These are listed as indirect holdings rather than new buy or sell transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/24/2026 - 08:37 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trieu Vuong

(Last)

(First)

(Middle)

29397 AGOURA RD SUITE 107

(Street)

AGOURA HILLS

CALIFORNIA

91301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncotelic Therapeutics, Inc. [ OTLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/24/2026⁽¹⁾	06/24/2026⁽¹⁾	P		115,000	A	$0.045	93,884,319	D
Common Stock	06/23/2026⁽¹⁾	06/23/2026⁽¹⁾	P		75,000	A	$0.045	93,769,319	D
Common Stock	06/22/2026⁽¹⁾	06/22/2026⁽¹⁾	P		65,000	A	$0.045	93,694,319	D
Common Stock								16,780,384	I	By Autotelic Inc.
Common Stock								6,872,529	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045.

	/s/ Vuong Trieu	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR